JP2018505199A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505199A5
JP2018505199A5 JP2017542048A JP2017542048A JP2018505199A5 JP 2018505199 A5 JP2018505199 A5 JP 2018505199A5 JP 2017542048 A JP2017542048 A JP 2017542048A JP 2017542048 A JP2017542048 A JP 2017542048A JP 2018505199 A5 JP2018505199 A5 JP 2018505199A5
Authority
JP
Japan
Prior art keywords
solvate
crystalline
accordance
data substantially
diffraction data
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017542048A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505199A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2016/050755 external-priority patent/WO2016128936A1/en
Publication of JP2018505199A publication Critical patent/JP2018505199A/ja
Publication of JP2018505199A5 publication Critical patent/JP2018505199A5/ja
Pending legal-status Critical Current

Links

JP2017542048A 2015-02-13 2016-02-12 (S)−5−ベンジル−N−(5−メチル−4−オキソ−2,3,4,5テトラヒドロベンゾ[b][1,4]オキサゼピン−3−イル)−4H−1,2,4−トリアゾール−3−カルボキサミドの結晶形 Pending JP2018505199A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562115674P 2015-02-13 2015-02-13
US62/115,674 2015-02-13
PCT/IB2016/050755 WO2016128936A1 (en) 2015-02-13 2016-02-12 Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide

Publications (2)

Publication Number Publication Date
JP2018505199A JP2018505199A (ja) 2018-02-22
JP2018505199A5 true JP2018505199A5 (cg-RX-API-DMAC7.html) 2019-03-22

Family

ID=55359562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017542048A Pending JP2018505199A (ja) 2015-02-13 2016-02-12 (S)−5−ベンジル−N−(5−メチル−4−オキソ−2,3,4,5テトラヒドロベンゾ[b][1,4]オキサゼピン−3−イル)−4H−1,2,4−トリアゾール−3−カルボキサミドの結晶形

Country Status (11)

Country Link
US (1) US10287280B2 (cg-RX-API-DMAC7.html)
EP (1) EP3256467A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018505199A (cg-RX-API-DMAC7.html)
KR (1) KR20170117472A (cg-RX-API-DMAC7.html)
CN (1) CN107207485A (cg-RX-API-DMAC7.html)
AU (1) AU2016217496B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017017411A2 (cg-RX-API-DMAC7.html)
CA (1) CA2976172A1 (cg-RX-API-DMAC7.html)
IL (1) IL253731A0 (cg-RX-API-DMAC7.html)
RU (1) RU2017131862A (cg-RX-API-DMAC7.html)
WO (1) WO2016128936A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3366684B1 (en) 2015-10-23 2020-09-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
EA201891620A1 (ru) 2016-02-05 2019-02-28 Денали Терапьютикс Инк. Ингибиторы взаимодействующей с рецептором протеинкиназы 1
EP3552017B1 (en) 2016-12-09 2022-02-23 Denali Therapeutics Inc. Compounds useful as ripk1 inhibitors
WO2019123219A1 (en) * 2017-12-20 2019-06-27 Glaxosmithkline Intellectual Property Development Limited Crystalline salt form of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
DK3788045T3 (da) 2018-05-03 2023-06-26 Rigel Pharmaceuticals Inc RIP1-hæmmende forbindelser og fremgangsmåder til fremstilling og anvendelse deraf
BR112020022420A2 (pt) 2018-05-03 2021-03-02 Rigel Pharmaceuticals, Inc. composto, composição farmacêutica, método, método para tratar uma doença em um indivíduo e método para produzir o composto
WO2020234716A1 (en) * 2019-05-17 2020-11-26 Glaxosmithkline Intellectual Property Development Limited Matrix composition comprising (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydrobenzo[b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide
JP7376218B2 (ja) 2019-09-06 2023-11-08 ライジェル ファーマシューティカルズ, インコーポレイテッド Rip1阻害化合物ならびにそれを作製および使用するための方法
MY198690A (en) 2019-09-06 2023-09-16 Rigel Pharmaceuticals Inc Rip1 inhibitory compounds and methods for making and using the same
KR102824962B1 (ko) 2019-11-07 2025-06-26 리겔 파마슈티칼스, 인크. 헤테로시클릭 rip1 억제 화합물
AR121717A1 (es) 2020-04-02 2022-06-29 Rigel Pharmaceuticals Inc Inhibidores de rip1k
TWI840311B (zh) 2020-07-01 2024-04-21 美商雷傑製藥公司 Rip1k抑制劑
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
KR20240132504A (ko) 2022-01-12 2024-09-03 데날리 테라퓨틱스 인크. (s)-5-벤질-n-(5-메틸-4-옥소-2,3,4,5-테트라하이드로피리도 [3,2-b][1,4]옥사제핀-3-일)-4h-1,2,4-트리아졸-3-카복사미드의 결정질 형태

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI648273B (zh) 2013-02-15 2019-01-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺類(三)

Similar Documents

Publication Publication Date Title
JP2018505199A5 (cg-RX-API-DMAC7.html)
RU2017131862A (ru) КРИСТАЛЛИЧЕСКИЕ ФОРМЫ (S)-5-БЕНЗИЛ-N-(5-МЕТИЛ-4-ОКСО-2,3,4,5-ТЕТРАГИДРОБЕНЗО[b][1,4]ОКСАЗЕПИН-3-ИЛ)-4H-1,2,4-ТРИАЗОЛ-3-КАРБОКСАМИДА
HRP20210748T1 (hr) Postupak priprave spojeva s aktivnošću inhibitora hiv integraze
JP2018024682A5 (cg-RX-API-DMAC7.html)
JP2022078315A5 (cg-RX-API-DMAC7.html)
JP2019194236A5 (cg-RX-API-DMAC7.html)
JP2008019161A5 (cg-RX-API-DMAC7.html)
JP2010530897A5 (cg-RX-API-DMAC7.html)
RU2010145171A (ru) Аналоги галихондрина в
JP2015063536A5 (cg-RX-API-DMAC7.html)
CN111788197A (zh) 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途
PE20250001A1 (es) Formas cristalinas novedosas
JP2007269812A5 (cg-RX-API-DMAC7.html)
JP2008544458A5 (cg-RX-API-DMAC7.html)
JP2014063186A5 (cg-RX-API-DMAC7.html)
JP2012502876A5 (cg-RX-API-DMAC7.html)
JP2012531408A5 (cg-RX-API-DMAC7.html)
JP2013532130A5 (cg-RX-API-DMAC7.html)
JP2020528637A5 (cg-RX-API-DMAC7.html)
JP2015199738A5 (cg-RX-API-DMAC7.html)
JP2025111617A5 (cg-RX-API-DMAC7.html)
JP2020513021A5 (cg-RX-API-DMAC7.html)
JP2019504865A5 (cg-RX-API-DMAC7.html)
JP2016534961A5 (cg-RX-API-DMAC7.html)
RU2016118796A (ru) Новая кристаллическая форма 2-{ 3-[2-(1-{ [3, 5-бис(дифторметил)-1н-пиразол-1-ил]ацетил} пиперидин-4-ил)-1, 3-тиазол-4-ил]-4, 5-дигидро-1, 2-оксазол-5-ил} -3-хлорфенилметансульфоната